Maaisha Osman
@maaisha.bsky.social
52 followers 35 following 54 posts
Health policy journalist • cinema on the side Signal: maaisha.07
Posts Media Videos Starter Packs
Pinned
maaisha.bsky.social
Hi, I’m Maaisha Osman. I cover federal health agencies, pharmaceutical tariffs and policies related to drug pricing.
My work: insidehealthpolicy.com/authors/Maai...

I also write about cinema. My latest essay is on Chris Marker’s La Jetée (1962): www.deepfocusreview.com/the-labyrint...
The Labyrinth of Memory in Chris Marker’s La Jetée
Journalist and film enthusiast Maaisha Osman shares an appreciation of Chris Marker’s experimental film La Jetée
www.deepfocusreview.com
Reposted by Maaisha Osman
jamielove.bsky.social
Robin Feldman on Pfizer obligations to SEC to disclose details of price deal with Trump.

insidehealthpolicy.com/share/151134
| InsideHealthPolicy.com
insidehealthpolicy.com
maaisha.bsky.social
In the wake of a mass shooting in Minnesota that left two children dead and 17 others injured, RFK Jr. again suggested a link between psychiatric medications -- particularly antidepressants -- and violent behavior.

But what do scientists say about such claims? 👇
Reposted by Maaisha Osman
dangaristo.bsky.social
Another EO about grants, this one directing the attorney general to investigate "lobbying" in the form of "taxpayer funds ... being spent on grants with highly political overtones."

Expect we'll see more targeting of universities by the DOJ.
Use of Appropriated Funds for Illegal Lobbying and Partisan Political Activity by Federal Grantees
MEMORANDUM FOR THE ATTORNEY GENERAL SUBJECT:       Use of Appropriated Funds for Illegal Lobbying and Partisan Political Activity by   Federal Grantees By
www.whitehouse.gov
maaisha.bsky.social
5. Even if a case had merit, @jamielove.bsky.social said, using it selectively means Trump is “acting like a mafia figure.”
maaisha.bsky.social
4. @jamielove.bsky.social said Harvard is not the only institution to have failed to disclose government funding tied to its patents. But he argued the Commerce Department’s action was less about fixing systemic compliance issues and more about targeting a political adversary.
James Packard Love (@jamielove.bsky.social)
I work at https://keionline.org/jamie. Best known for work on intellectual property rights, and find most interesting ways to reform incentives and also build out global norms and mechanisms to incr...
jamielove.bsky.social
maaisha.bsky.social
3. In 2019, the watchdog group Knowledge Ecology International (KEI) urged NIH to investigate whether Harvard’s Dana-Farber Cancer Institute failed to disclose federal funding on six lucrative cancer immunotherapy patents co-assigned to the institute.
maaisha.bsky.social
2. While investigations have shown that many top universities have skirted disclosure laws, watchdog groups say that this probe appears less about enforcing the law uniformly & more about targeting Harvard in a political battle over control of lucrative taxpayer-backed inventions.
maaisha.bsky.social
1. NEW: The U.S. Commerce Department has launched an aggressive review of Harvard University’s management of patents tied to federally funded research, accusing the Ivy League institution of violating disclosure laws under the Bayh-Dole Act. 👇
maaisha.bsky.social
@jamielove.bsky.social said Harvard is not the only institution to have failed to disclose government funding tied to its patents. But he argued the Commerce Department’s action was less about fixing systemic compliance issues and more about targeting a political adversary.
maaisha.bsky.social
3. In 2019, the watchdog group Knowledge Ecology International (KEI) urged NIH to investigate whether Harvard’s Dana-Farber Cancer Institute failed to disclose federal funding on six lucrative cancer immunotherapy patents co-assigned to the institute.
maaisha.bsky.social
2. While investigations have shown that many top universities have skirted disclosure laws, watchdog groups say that this probe appears less about enforcing the law uniformly & more about targeting Harvard in a political battle over control of lucrative taxpayer-backed inventions.
maaisha.bsky.social
Some generic drugs are exempted from the deal.
Link for subscribers: insidehealthpolicy.com/inside-drug-...
insidehealthpolicy.com
maaisha.bsky.social
NEW: European pharmaceutical imports will be hit with a 15% tariff under the U.S.-EU agreement when the Section 232 duties are implemented, a White House official said today, clarifying that the rate is the maximum that will apply to EU pharma products.
maaisha.bsky.social
NEW: NIH Director met privately with current and former agency employees on Monday where he affirmed support for dissent, academic freedom, and LGBTQ+ health research “as long as it’s not ideological.”
They spoke about grant terminations, forward funding model and more.
| InsideHealthPolicy.com
insidehealthpolicy.com
maaisha.bsky.social
FDA Commissioner Marty Makary has tapped George Tidmarsh -- former CEO of several biopharma companies -- to lead CDER, a pick that contradicts Makary’s repeated vows to purge industry influence from the health agency.

insidehealthpolicy.com/share/149608
| InsideHealthPolicy.com
insidehealthpolicy.com
maaisha.bsky.social
Can’t wait :)
letterboxd.social
Exclusive look at the new trailer for Stanley Kubrick’s Barry Lyndon, ahead of its new 4K restoration to celebrate the film’s 50th anniversary 🌹 

The film will be back in cinemas from July 18 across the UK and internationally via Park Circus Films
maaisha.bsky.social
Rather than pursuing an outright ban that could spark legal battles, HHS is weighing targeted measures to make DTC drug ads harder and costlier to produce. An industry insider says the pullback is unlikely without regulation & warned an outright ban could leave a vacuum for unregulated misinfo.
| InsideHealthPolicy.com
insidehealthpolicy.com
Reposted by Maaisha Osman
scott-delaney.bsky.social
To be clear, Judge Young is ruling that the NIH terminations were neither "reasoned" nor "reasonable" based on the legal standard previously set forth by the Supreme Court for reviewing agency actions (e.g., terminations) under the APA.

This is very good for plaintiffs.